Compare Hut 8 Corp (HUT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Twist Bioscience Corp — how do they compare? Hut 8 Corp trades at $84.27 (market cap $9.82B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Hut 8 Corp and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Twist Bioscience Corp for 27 Days on average.
| HUT | TWST | |
|---|---|---|
Market Cap | $9.82B | $10.08B |
Volume | 10,272,678 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $133.02 | $205.00 |
52-Week Low | $33.76 | $25.45 |
Typical Hold Time | 11 Days | 27 Days |
Enterprise Value | $17.25B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $84.27, down 5.63% today, with a bearish technical outlook despite oversold RSI readings. The company reported negative earnings in recent quarters, missing expectations, with a net income margin of -188.59% for 2026. Recent positive developments include securing a $1.07 billion credit facility and analyst optimism around AI infrastructure contracts.
While analyst consensus is strongly bullish with a $162.69 price target, significant execution risks persist given negative profitability and cash flow challenges. The stock offers high potential upside if AI infrastructure contracts materialize but carries substantial risk from ongoing losses and competitive pressures in the digital infrastructure space.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
